// App-Quantinova.ai

: HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2-overexpressing metastatic or advanced gastric/GEJ adenocarcinoma— Overall survival analysis.

Researchers

Presenter

  • Marina Maglakelidze

Principal Investigators

  • Dinara E. Ryspayeva

  • Zoran Andric

  • Zoran Petrovic

  • Iurie Bulat

  • Ivan Nikolic

  • Rajnish Nagarkar

  • Ursula Wiedermann

  • Brent A. Blumenstein

  • Leslie Mi Ok Chong

  • Nicholas Ede

  • Bonnie Nixon

  • Sharon Yavrom

  • Giovanni Selvaggi

  • Anthony J. Good

  • Tanuj Chawla

Medical Centers

  • ARENSIA Exploratory Medicine, Institute of Oncology, Chisinau, Moldova, Republic of

  • Medical University of Vienna, Vienna, Austria

  • Trial Architecture Consulting, Chevy Chase, MD

  • Tata Medical Centre, Kolkata, India

  • Curie Manavata Cancer Center, Nashik, India

  • Clinic of hematology, Military Medical Academy, Belgrade, Serbia

  • Oncology Institute of Vojvodina, Sremska Kamenica, Serbia

  • LLC ARENSIA Exploratory Medicine, Tblisi, Georgia

  • Clinical Hospital Centre Bezanijska Kosa, Beograd, Serbia

  • Engeneic, Sydney, Australia

  • ARENSIA Exploratory Medicine Research Unit and National Cancer Institute, Kyiv, Ukraine

Locations

  • Ukraine

  • Republic of South Korea

  • United States

  • Australia

  • Serbia

  • India

  • Austria

  • Georgia

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Peptide vaccine

  • Capecitabine

  • Oxaliplatin

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • NCT02795988

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved